Bayer's Legal Win Lifts the Stock, but mwb Sees No Change to the Cash Flow Math
Published on 10/31/2026 at 10:01 | Editorial boerse-global.de
Bayer shares rose 5.1% yesterday as investors cheered a courtroom victory for the company's Monsanto subsidiary in a glyphosate case, yet the analysts at mwb are drawing a sharp line between a better legal outlook and any change to the money Bayer will actually have to pay out.
The research house reaffirmed its buy rating on the German life-sciences group with a price target of 65 euros, but made clear it does not expect the recent Roundup win to move provisions or cash flow forecasts. That distinction matters: a favorable verdict can improve how investors size up litigation risk without touching the expected payment streams that underpin the valuation.
A Unanimous Jury Verdict in St. Louis
In the Roundup case known as Aretino, a jury in St. Louis unanimously rejected the claims of three women. Bayer described the proceeding as the first Roundup trial since the US Supreme Court's ruling in the Durnell case, and Reuters framed the outcome as the company's first glyphosate trial win since that decision. The jurors dismissed all claims tied to product design, misrepresentation and negligence.
What the verdict does not do is substitute for the broader settlement process. Roughly 65,000 Roundup lawsuits remain outstanding in the United States, according to Reuters, while a Missouri court weighs a proposed $7.25 billion settlement. The capped payments under that deal would taper over a period of up to 21 years, and final judicial approval is still pending. The three plaintiffs in the Aretino case are not part of the proposed settlement, and the jury decision sets no binding precedent.
Should investors sell immediately? Or is it worth buying Bayer?
Expectations on the settlement are running ahead of the paperwork. JPMorgan analyst Richard Vosser anticipates approval in the near term, while Markus Manns of Union Investment expects that more plaintiffs will likely opt for an out-of-court resolution. Both are forecasts; neither the final sign-off nor a higher take-up rate is assured.
Debt Reduction Stays on Track
mwb remains confident about Bayer's deleveraging path, projecting net debt of 26.674 billion euros by the end of 2026 — a forecast rather than a figure already on the balance sheet. The positive investment case, in the analysts' view, does not rest on the assumption that the latest court success frees up cash right away. What counts is whether legal progress translates into more reliable financial planning.
The next hard checkpoint arrives on November 3, 2026, when Bayer publishes its third-quarter 2026 report at 07:30 CET. A media event is scheduled for 10:00, followed by an investor video call at 14:00. That date should pull attention back toward the operating business after a run of legal headlines.
Pipeline News Adds to the Momentum
Clinical and regulatory developments have given the stock additional support. In China, Asundexian won marketing approval under the brand name Sunharbo for reducing stroke risk in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Bayer says it is the first FXIa inhibitor cleared anywhere in the world.
Bayer at a turning point? This analysis reveals what investors need to know now.
Just over a week ago, the company also reported results from the Phase III DASL-HiCaP study of darolutamide. In prostate cancer patients at high risk of recurrence, the drug — added to androgen deprivation and radiotherapy — cut the risk of metastases or death by 58% versus placebo over a median observation period of 3.8 years. The four-year metastasis-free survival rate came in at 95% against 88% on placebo. Bayer noted that darolutamide is not yet approved for this treatment setting.
For holders weighing the buy recommendation, the two threads stay separate: mwb still sees upside, but is not yet baking a litigation-driven revision to provisions or cash flow into its numbers. The next meaningful step on legal risk would be not another favorable ruling but a firmer foundation for the payments still to come.
Ad
Bayer Stock: New Analysis - 31 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
